

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 0575/61136/JPW/ADM		Serial No. 09/766,944	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant: Andrew R. Marks and Steven O. Marx			
				Filing Date: January 22, 2001		Group Art Unit 1642	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>amb</i>		Braun-Dullaues, R. C., et al. (1997). Loss of p27kip1 and induction of Cdk1 in the rat carotid artery following balloon catheter injury. In vivo and in vitro influence of rapamycin. FASEB J 11, A153 (abstract) (Exhibit 2).					
↓		Braun-Dullaues, R. C., Mann, M. J., Ziegler, A., von der Leyen, H. E., and Dzau, V. J. (1999). A novel role for the cyclin-dependent kinase inhibitor p27kip1 in angiotension II-stimulated vascular smooth muscle cell hypertrophy. J. Clin. Invest. 104, 815-823 (Exhibit 3).					
↓		Cao, W., Mohacsi, P., Shorthouse, R., Pratt, R., and Morris, R. (1995). Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis: inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 59, 390-395 (Exhibit 4).					
EXAMINER		<div style="display: flex; justify-content: space-between;"> <i>amb</i> DATE CONSIDERED 2/11/2003 </div>					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Andrew R. Marks and Steven O. Marx
 U.S. Serial No.: 09/766,944
 Filed: January 22, 2001
 Exhibit 1

Form PTO-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. 0575/61136/JPW/ADM	U.S. Serial No. 09/766,944
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Applicant: Andrew R. Marks and Steven O. Marx	
		Filing Date January 22, 2001	Group Art Unit 1642
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	Gallo, R., Padurean, A., Jayaraman, T., Marx, S. O., Roque, M., Adelman, S., Chesebro, J., Fallon, J., Fuster, V., Marks, A. R., and Badimon, J. J. (1999). Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. <i>Circulation</i> 99, 2164-2170 (Exhibit 5).		
	Gregory, C., Huie, P., Billingham, M., and Morris, R. (1993). Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. <i>Transplantation</i> 55, 1409-1418 (Exhibit 6).		
	Luo, Y., Marx, S. O., Kiyokawa, H., Koff, A., Massague, J., and Marks, A. R. (1996). Rapamycin resistance tied to defective regulation of p27 ^{Kip1} . <i>Mol. Cell. Biol.</i> 16, 6744-6751 (Exhibit 7).		
	Marx, S. O., Jayaraman, T., Go, L. O., and Marks, A. R. (1995). Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. <i>Circ. Res.</i> 76, 412-417 (Exhibit 8).		
	Poon, M., Marx, S. O., Gallo, R., Badimon, J. J., Taubman, M. B., and Marks, A. R. (1996). Rapamycin inhibits vascular smooth muscle cell migration. <i>J. Clin. Invest.</i> 98, 2277-2283 (Exhibit 9).		
	Poston, R. S., Billingham, M., Hoyt, E. G., Pollard, J., Shorthouse, R., Morris, R. E., and Robbins, R. C. (1999). Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. <i>Circulation</i> 100, 67-74 (Exhibit 10).		
	Sousa, J. E., Costa, M. A., Abizaid, A., Abizaid, A. S., Feres, F., Pinto, I.M.F. et al. (2000) Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries. A quantitative coronary angiography and three-dimensional intravascular ultrasound study. <i>Circulation</i> 102, r54-r57 (Exhibit 11).		
	Steeg, P. S., and Abrams, J. S. (1997). Cancer prognostics: Past, present and p27. <i>Nature Med.</i> 3, 152-154 (Exhibit 12).		
EXAMINER			
DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

RECEIVED

JUN 04 2002

TECH CENTER 1600/2900

Sheet 1 of 1

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 61136/JPW/ADM	Serial No. 09/766,944
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Applicants: Andrew R. Marks and Steven O. Marx	
		Filing Date: January 22, 2001	Group Art Unit 1642

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<i>amh</i>		9 9 0 3 5 0 8	1/28/99	PCT	<u> </u>	<u> </u>		
<i>amh</i>		9 9 6 5 9 3 9	12/23/99	PCT	<u> </u>	<u> </u>		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER <i>amh Harris</i>	DATE CONSIDERED <i>9/11/2003</i>
----------------------------	----------------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Andrew R. Marks and
Steven O. Marx
U.S. Serial No.: 09/766,944
Filed: January 22, 2001
Exhibit I